Neurofibromatosis Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The neurofibromatosis treatment market size is expected to grow from USD 14.71 billion in 2025 to USD 16.59 billion in 2026 and is forecast to reach USD 30.25 billion by 2031 at 12.77% CAGR over 2026-2031. This report is segmented by Disease Type (NF Type 1, NF Type 2, Schwannomatosis), Therapy Type (MEK Inhibitors, Pain-Management, Surgical Interventions, and More), Treatment Stage (First-Line, Recurrent Disease, Symptomatic, Advanced Disease Management), End User (Hospitals, Specialty Centers, and More), and Geography (North America, Europe, and More). Forecasts are Provided in Terms of Value (USD).

Global Neurofibromatosis Treatment Market Trends and Insights

Expansion of Approved MEK-Inhibitor Labels Across Age Groups

The FDA approved selumetinib for adults with NF1 and symptomatic, inoperable plexiform neurofibromas on November 19, 2025. The KOMET Phase III trial included 145 patients across 13 countries. It reported a confirmed overall response rate of 20% for selumetinib and 5% for placebo, with p=0.011. The neurofibromatosis treatment market gained a wider adult treatment base through this approval. FDA approved mirdametinib on February 11, 2025, for adults and children aged 2 years and older with NF1-PN. The ReNeu Phase 2b trial reported confirmed response rates of 41% in adults and 52% in children. The European Commission conditionally authorized EZMEKLY in July 2025 for adults and children with NF1-PN. Differences in cardiac safety, tolerability, and routine monitoring could shape physician choice before comparative studies become available.

Rising Diagnosis Through Genetic Testing and Specialist Referral

Combined DNA and cDNA sequencing can achieve a diagnostic yield above 95.9% for NF1. Traditional genomic DNA methods had detected 60% to 90% of pathogenic variants. Splicing variants account for 22% to 30% of disease-causing alterations and can be missed without broader testing. A 2025 study of 148 Turkish pediatric patients found molecular variants in 94.5% of cases through NGS. Adding MLPA increased the cumulative yield to 95.9%. Earlier molecular confirmation can improve referrals for plexiform neurofibroma surveillance and treatment assessment. The neurofibromatosis treatment market may therefore gain eligible patients before symptom burden becomes severe. A Korean assessment of 1,917 individuals achieved an 81.6% cumulative yield after reclassification and whole-genome sequencing.

High Treatment Cost and Reimbursement Friction

Ireland estimated annual selumetinib treatment costs at EUR 204,001 (USD 236,691) for a 10-year-old and EUR 305,642 (USD 354,619) for an 18-year-old. The assessment reported ICERs from EUR 170,774 (USD 198,139) to EUR 332,319 (USD 385,571) per QALY against a EUR 50,000 (USD 58,012) reference value. It indicated that price reductions of 70% to 84% would be needed for coverage under the assessed Irish thresholds. High list prices can delay reimbursement and constrain prescribing even after regulatory approval. Payers that do not fund treatment have less reason to expand specialist capacity or diagnostic infrastructure. This can restrict diagnosis and treatment at the same time. Dutch recommendations also included prescribing and monitoring conditions for selumetinib. The neurofibromatosis treatment market will continue to face different uptake rates across national reimbursement systems.

Other drivers and restraints analyzed in the detailed report include:

• Increased Investment in Rare-Disease Drug Development
• AI-Enabled Discovery for Genetically Defined Tumor Biology
• Long-Term Toxicity Monitoring and Treatment Discontinuation

Segment Analysis

NF1 held 38.31% of the neurofibromatosis treatment market share in 2025. Its prevalence affected 1 in 2,500 to 3,000 people globally. The disease also had commercial support from approved MEK inhibitors. NF1 is expected to record the highest disease-type growth through 2031. This pattern supports continued revenue concentration in the neurofibromatosis treatment market. It also reflects the greater number of approved treatment options for NF1 than for other forms of neurofibromatosis.

Japan approved bevacizumab for NF2 in June 2026. The approval was the first for a medicine for NF2 and followed the BeatNF2 Phase II study of 62 patients at 12 Japanese institutions. NF2 and schwannomatosis still depend largely on surgery and investigational care outside this indication. Their underlying biology differs from NF1 because of the loss of the Merlin tumor suppressor. This difference limits the direct transfer of the NF1 MEK inhibitor approach. PRIME-NF2 is evaluating multi-agent approaches more broadly. These disease areas remain less developed portions of the neurofibromatosis treatment market, even as research activity rises.

MEK inhibitors represented 26.24% of total revenue in 2025. They remain the commercial treatment base because selumetinib, mirdametinib, and luvometinib each target MEK1/2 within the MAPK pathway. Gene-based therapies are forecast to grow at a 17.42% CAGR through 2031. The neurofibromatosis treatment market size for gene-based therapies is shaped by pipeline activity rather than current commercial scale. No gene therapy has regulatory approval for an NF subtype. This difference is important when considering near-term sales and later clinical potential.

A September 2025 Nature Communications study reported an AAV vector proof-of-concept for NF1-related tumors. The study found significant tumor growth suppression in xenograft models of MPNST, neurofibromas, and gliomas. A 2026 Communications Biology study reported 43% tumor penetrance in treated mice and 83% in controls. These findings provide preclinical support for later human testing. Clinician choice among current MEK inhibitors may increasingly depend on tolerability and formulation convenience. Pain-management therapies, surgery, and radiation remain relevant where access to MEK inhibitors is restricted. The STARFISH platform trial is also assessing treatments for schwannomatosis-related pain.

Complete Report Scope:

• By Disease Type
  • Neurofibromatosis Type 1
  • Neurofibromatosis Type 2
  • Schwannomatosis
• By Therapy Type
  • MEK Inhibitors
  • Pain-Management Therapies
  • Surgical Interventions
  • Radiation Therapy
  • Gene-Based Therapies
  • Other Therapy Types
• By Treatment Stage
  • First-Line Therapy
  • Recurrent Disease Management
  • Symptomatic Treatment
  • Advanced Disease Management
• By End User
  • Hospitals
  • Specialty Centers
  • Academic and Research Institutes
  • Other End Users
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 42.61% of global revenue in 2025. The United States received major approvals for pediatric selumetinib in 2020, adult selumetinib in 2025, and mirdametinib in February 2025. Reimbursement access is more developed than in many other regions, although access remains incomplete. Canada’s pan-Canadian Pharmaceutical Alliance reached a letter of intent on Koselugo reimbursement in December 2024. Quebec subsequently made its first provincial formulary listing. These developments strengthened public coverage after years of access through expanded criteria.

Europe has uneven reimbursement conditions across countries. Germany’s G-BA issued an August 2026 resolution that listed annual selumetinib treatment costs of EUR 81,237 (USD 94,254) to EUR 97,443 (USD 113,057) per patient - issued a cost-comparison recommendation for mirdametinib in children aged 2 to 17. Germany and the United Kingdom are, therefore, more accessible than several European markets. The Netherlands and Ireland recorded adverse assessments for selumetinib without negotiated price adjustments. France, Spain, Italy, and the Rest of Europe remain behind in reimbursement execution. These variations will continue to affect the neurofibromatosis treatment market across Europe.

Asia-Pacific is forecast to grow at a 15.25% CAGR through 2031, the fastest regional rate in the neurofibromatosis treatment market. China approved Fosun Pharma’s domestically developed luvometinib for pediatric NF1-PN in May 2025. Japan approved bevacizumab for NF2 in June 2026. India, Australia, and South Korea have substantial addressable populations but lag in diagnostic infrastructure and orphan-drug reimbursement. The Middle East and Africa, and South America rely more on compassionate use and hospital decisions than national coverage. Brazil, Argentina, the GCC, and South Africa have specialist or academic capacity, but funding constraints limit broad medicine uptake. These areas are expected to contribute more to generics and surgical care than to premium MEK inhibitor or gene-therapy sales through 2031.

List of Companies Covered in this Report:

• AstraZeneca
• Bayer
• Chugai Pharmaceutical
• Roche
• Fosun Pharmaceutical Group Co., Ltd.
• Healx Limited
• Kechow Pharma, Inc.
• Merck
• NFlection Therapeutics, Inc.
• Novartis
• Pasithea Therapeutics Corp.
• Pfizer
• Recursion Pharmaceuticals
• Sanofi
• Vivace Therapeutics, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support